Current Clinical Trials

CLINICAL TRIALS CURRENTLY AVAILABLE FOR PTCL & CTCL PATIENTS:

• NCT01482962: Alisertib (MLN8237) or Investigator’s Choice in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
• NCT01466881: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
• NCT01796002: Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma
• NCT01611142: Study of KW-0761 (Mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma
• NCT01590732: Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
• NCT01336920: Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
• NCT01777152: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
• NCT01352520: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
• NCT01738594: Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
• NCT01637090: Everolimus in Treating Cutaneous T-Cell Lymphoma
• NCT01578499: A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
• NCT01839097: Phase I Dose Finding Study of Belinostat Plus CHOP for Treatment of Patients with PTCL
• NCT01728805: Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
• NCT01626664: KW-0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
• NCT00047060: SCT Therapy with Campath-1H for Treating Advanced Mycosis Fungoides (MF) and Sezary Syndrome (SS)
• NCT01805037:  Phase I/II Study of Brentuximab Vedotin + Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
• NCT01660451: Open-label, Uncontrolled Phase II Trial of Intravenous P13K Inhibitor BAY80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas
• NCT01567709: Alisertib in Combination with Vorinostat in Treating Patients with Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma or Peripheral T-Cell Lymphoma
• NCT01742793: An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed/Refractory Hodgkin Lymphoma, Mature T-Cell Lymphoma and Multiple Myeloma
• NCT01431209: Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
• NCT01678443: Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies
• NCT01261247: Panobinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
• NCT01703949: Brentuximab Vedotin in Treating Patients with Relapsed or Refractory CD30+ Lymphoma